J Korean Orthop Assoc.  2015 Dec;50(6):438-443. 10.4055/jkoa.2015.50.6.438.

Current Strategy of Chemotherapy for Bone Tumors

• Kim HS
• Rha SY

• KMID: 2185084
• DOI: http://doi.org/10.4055/jkoa.2015.50.6.438

Abstract

Despite the rarity of primary bone tumors, osteosarcoma and Ewing sarcoma are the most common primary malignant bone tumors in children and adolescents. Multiagent chemotherapy regimens for neoadjuvant and adjuvant treatment remarkably improved the survival outcome for patients with osteosarcoma and Ewing sarcoma, therefore, most patients are now limb-salvage candidates. However, survival rate reached a plateau for last decades and is still unsatisfactory in the metastatic and relapse setting. Therefore, as seen in denosumab in giant cell tumor, further clinical trials based on molecular mechanism are warranted. This article reviews the current state of the art of systemic chemotherapy by focusing on the clinical heterogeneity of each subtype.

Keyword

bone tumor; chemotherapy

MeSH Terms

Adolescent
Child
Drug Therapy*
Giant Cell Tumors
Humans
Osteosarcoma
Population Characteristics
Recurrence
Sarcoma, Ewing
Survival Rate
Denosumab